Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer

Inclusion Criteria

• •Indication:
• •Oligometastases (1-5) in castration-resistant prostate carcinoma
• •Patient with good general condition (WHO 0-1)
• •Histologically confirmed prostate carcinoma
• •After definitive local therapy, e.g. radical prostatectomy or definitive radiotherapy (also after neo-adjuvant hormone therapy, after postoperative radiotherapy).
• •PSA progression under ongoing androgen deprivation (defined as three consecutive increasing PSA values at intervals of \> 4 weeks and testosterone in the castration area \<50ng/dl or \<1.73nmol/)
• •Minimum duration of androgen deprivation 6 months before inclusion in study
• •Present complete staging (max. 6 weeks old), preferably by means of PET hybrid imaging with prostate-specific PET tracer
• •Imaging detection of individual active or progressive metastases (max. 5, depending on location) that are accessible to local ablative radiotherapy (histological confirmation of the metastases is not required)
• •No parallel participation to further clinical therapy trials up to 4 weeks before and after radiation therapy
• •Individual case discussion in an interdisciplinary tumor board
• •Patient's ability to consent and written consent